Erasca (ERAS) Hits 4-Year High Ahead of ERAS-0015 Trial Results

Erasca Inc. (NASDAQ:ERAS) is one of the 10 Stocks With Double-Digit Returns.

Erasca rallied for a 5th straight session on Monday to hit a new four-year high, as investors positioned portfolios ahead of the results of its clinical study for its pancreatic cancer treatment candidate, ERAS-0015.

In intra-day trading, the stock surged to a record high of $21.85 before trimming a few cents to finish the session just up by 14.20 percent at $21.71 apiece. Year-to-date, the stock was already up by 483.6 percent.

5 Best Healthcare Penny Stocks to Buy According to Hedge Funds

Photo by Tima Miroshnichenko on Pexels

In a notice earlier in the year, Erasca Inc. (NASDAQ:ERAS) said that additional data from the first phase study of ERAS-0015 are expected to be announced in the first half of 2026.

Optimism was further supported by earlier announcements that ERAS-0015 holds a “best-in-class” potential, as underscored by the partial responses at a low dosage of 8 mg daily across multiple tumor types, alongside favorable safety data.

“This clinical progress and the successful upsized public offering heighten excitement in our RAS-targeting franchise and strengthen our financial position as we further advance clinical development,” Erasca Inc. (NASDAQ:ERAS) Chairman and CEO Jonathan Lim said.

Erasca Inc. (NASDAQ:ERAS) also expanded its worldwide rights to develop and commercialize ERAS-0015 to China, Hong Kong, and Macau, sparking revenue growth opportunities in these areas.

In addition, it inked a collaboration and supply agreement with Tango Therapeutics Inc. to evaluate the efficacy of ERAS-0015 when combined with the latter’s PRMT5 inhibitor, vopimetostat.

The combination represents a promising opportunity to redefine the standard of care in patients with MTAP-deleted RAS-mutant (MTAPdel RASm) cancers, where treatment options remain limited, Erasca Inc. (NASDAQ:ERAS) said.

While we acknowledge the risk and potential of ERAS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ERAS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.